The online version of this article (doi:10.1007/s10549-016-4085-4) contains supplementary material, which is available to authorized users.
Mary Pritzlaff and Pia Summerour have contributed equally to this work.
Genetic predisposition to male breast cancer (MBC) is not well understood. The aim of this study was to better define the predisposition genes contributing to MBC and the utility of germline multi-gene panel testing (MGPT) for explaining the etiology of MBCs.
Clinical histories and molecular results were retrospectively reviewed for 715 MBC patients who underwent MGPT from March 2012 to June 2016.
The detection rate of MGPT was 18.1% for patients tested for variants in 16 breast cancer susceptibility genes and with no prior BRCA1/2 testing. BRCA2 and CHEK2 were the most frequently mutated genes (11.0 and 4.1% of patients with no prior BRCA1/2 testing, respectively). Pathogenic variants in BRCA2 [odds ratio (OR) = 13.9; p = 1.92 × 10−16], CHEK2 (OR = 3.7; p = 6.24 × 10−24), and PALB2 (OR = 6.6, p = 0.01) were associated with significantly increased risks of MBC. The average age at diagnosis of MBC was similar for patients with (64 years) and without (62 years) pathogenic variants. CHEK2 1100delC carriers had a significantly lower average age of diagnosis (n = 7; 54 years) than all others with pathogenic variants (p = 0.03). No significant differences were observed between history of additional primary cancers (non-breast) and family history of male breast cancer for patients with and without pathogenic variants. However, patients with pathogenic variants in BRCA2 were more likely to have a history of multiple primary breast cancers.
These data suggest that all MBC patients regardless of age of diagnosis, history of multiple primary cancers, or family history of MBC should be offered MGPT.
Supplementary material 1 (DOCX 31 kb)10549_2016_4085_MOESM1_ESM.docx
The NCCN Clinical Practice Guidelines in Oncology™ Genetic/Familial High-Risk Assessment: Breast and Ovarian V2.2016. National Comprehensive Cancer Network, Inc. 2016. http://www.nccn.org/. Accessed 22 Sept 2016
Breast Cancer Linkage Consortium (1999) Cancer Risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310–1316 CrossRef
Pesaran T, Karam R, Huether R et al (2016) Beyond DNA: an integrated and functional approach for classifying germline variants in breast cancer genes. Int J Breast Cancer 2016:1–10 CrossRef
Norquist BM, Harrell MI, Brady MF et al (2015) Inherited mutations in women with ovarian carcinoma. JAMA Oncol. doi: 10.1001/jamaoncol.2015.5495
Surveillance, Epidemiology, and End Results (SEER) Program ( www.seer.cancer.gov) SEER Stat Fact Sheets: Prostate Cancer (SEER 18 2009-2013). National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch. https://seer.cancer.gov/statfacts/html/prost.html. Accessed 9 Sept 2016
LaDuca H, McFarland R, Gutierrez S et al (2016) Taming concerns regarding the accuracy of laboratory clinical data: a detailed comparative analysis. Abstract, American Society of Human Genetics: ACMG Abstract 741F
- Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results
Jill S. Dolinsky
David E. Goldgar
Fergus J. Couch
Elizabeth C. Chao
- Springer US
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II